Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio, a Nasdaq-listed biotechnology company, announced its Q2 2026 financial results showing a significant reduction in net loss compared to the previous year and a strong cash position of approximately $69.9 million expected to fund operations beyond 2027. The company is exploring acquisitions and in-licensing opportunities to expand its the…